Sanofi enjoys solid Q1, despite continuing erosion of Lantus sales in U.S.

Fierce Pharma --------- Sanofi CEO Olivier Brandicourt has been criticized for failing to pull off a couple of big acquisitions, but his more mundane deal to get Boehringer Ingelheim’s consumer health business has paid off. It helped the French drugmaker overcome continuing hits to its diabetes franchise and turn in a surprisingly strong first quarter. The drugmaker today reported revenues were up 8.6% in constant currencies to €8.6 billion ($9.4 billion). Earnings per share were €1.42, up 3%, beating analyst forecasts. “We have started the year with robust growth driven by specialty care and vaccines as well as good performance in emerging markets. Our top line in the first quarter also benefited from the integration of the Boehringer Ingelheim CHC and European vaccine businesses,” Brandicourt said in the earnings release. “At the same time, the simplified organization continues to contribute to Sanofi’s financial performance.” To learn more click on the picture below to read the article.